Recombinant tissue plasminogen activator injected into the vitreous cavity may penetrate the retinal veins of a porcine model of vascular occlusion
- PMID: 16540487
- PMCID: PMC1857170
- DOI: 10.1136/bjo.2005.089037
Recombinant tissue plasminogen activator injected into the vitreous cavity may penetrate the retinal veins of a porcine model of vascular occlusion
Abstract
Aim: To determine if recombinant tissue plasminogen activator (rtPA) injected into the vitreous cavity can penetrate the retinal vessels of porcine eyes with or without vascular occlusion.
Methods: Eight eyes (group I) of four pigs underwent clamping of the optic nerve flush with the globe for 90 minutes. One hour after reperfusion, one eye of each pig was injected with 75 microg of rtPA, and the fellow eye was injected with balanced salt solution (BSS). Eyes were processed for immunohistochemistry. Four additional eyes (group II) of two pigs were subjected to the same injections, but without optic nerve clamping.
Results: After reperfusion, the clinical picture was similar to that of a central retinal vein occlusion. Immunoperoxidase staining showed rtPA only in the retinal veins but not the retinal arteries in all eyes injected with rtPA in both groups I and II. Those eyes also showed intense rtPA staining at the level of the internal limiting membrane (ILM). No staining was seen at the level of the ILM or inside the retinal vessels in the BSS injected eyes. Immunofluorescence staining showed intense staining at the level of the ILM, but not inside the retinal vessels in the rtPA-injected eyes.
Conclusions: rtPA may penetrate the retinal veins, but not the arteries of porcine eyes with and without vascular occlusion. The ILM may play a part in preventing rtPA penetration.
Conflict of interest statement
Competing interests: none.
Similar articles
-
Intravitreal tenecteplase (metalyse) for acute management of retinal vein occlusions.Invest Ophthalmol Vis Sci. 2013 Jul 22;54(7):4910-8. doi: 10.1167/iovs.13-11967. Invest Ophthalmol Vis Sci. 2013. PMID: 23766477
-
Basic fibroblast growth factor stimulates 3H-thymidine uptake in retinal venular and capillary endothelial cells in vivo.Invest Ophthalmol Vis Sci. 1990 Jul;31(7):1238-44. Invest Ophthalmol Vis Sci. 1990. PMID: 2365555
-
Retinal vein cannulation with prolonged infusion of tissue plasminogen activator (t-PA) for the treatment of experimental retinal vein occlusion in dogs.Am J Ophthalmol. 2004 Nov;138(5):829-39. doi: 10.1016/j.ajo.2004.06.083. Am J Ophthalmol. 2004. PMID: 15531319
-
Surgical treatments of central retinal vein occlusion.Semin Ophthalmol. 2003 Sep;18(3):142-6. doi: 10.1076/soph.18.3.142.29803. Semin Ophthalmol. 2003. PMID: 15513475 Review.
-
Literature review of recombinant tissue plasminogen activator used for recent-onset submacular hemorrhage displacement in age-related macular degeneration.Ophthalmologica. 2013;229(1):1-14. doi: 10.1159/000343066. Epub 2012 Oct 12. Ophthalmologica. 2013. PMID: 23075629 Review.
References
-
- Clarkson J. Central retinal vein occlusion. In: Ryan S, ed. Retina. St Louis: Mosby, 19941379
-
- Oncel M, Peyman G A, Khoobehi B. Tissue plasminogen activator in the treatment of experimental retinal vein occlusion. Retina 198991–7. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources